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Abstract
Craniosynostosis (CS), the premature ossification of cranial sutures, is attributed to increased osteogenic potential of
resident osteoblasts, yet the contribution of the surrounding extracellular matrix (ECM) on osteogenic differentiation is
unclear. The osteoblast-secreted ECM provides binding sites for cellular adhesion and regulates the transport and signaling
of osteoinductive factors secreted by the underlying dura mater. The binding affinity of each osteoinductive factor for the
ECM may amplify or mute its relative effect, thus contributing to the rate of suture fusion. The purpose of this paper was to
examine the role of ECM composition derived from calvarial osteoblasts on protein binding and its resultant effect on cell
phenotype. We hypothesized that potent osteoinductive proteins present during sutural fusion (e.g., bone morphogenetic
protein-2 (BMP-2) and transforming growth factor beta-1 (TGF-b1)) would exhibit distinct differences in binding when
exposed to ECMs generated by human calvarial osteoblasts from unaffected control individuals (CI) or CS patients.
Decellularized ECMs produced by osteoblasts from CI or CS patients were incubated in the presence of BMP-2 or TGF-b1,
and the affinity of each protein was analyzed. The contribution of ECM composition to protein binding was interrogated by
enzymatically modulating proteoglycan content within the ECM. BMP-2 had a similar binding affinity for each ECM, while
TGF-b1 had a greater affinity for ECMs produced by osteoblasts from CI compared to CS patients. Enzymatic treatment of
ECMs reduced protein binding. CS osteoblasts cultured on enzymatically-treated ECMs secreted by osteoblasts from CI
patients in the presence of BMP-2 exhibited impaired osteogenic differentiation compared to cells on untreated ECMs.
These data demonstrate the importance of protein binding to cell-secreted ECMs and confirm that protein-ECM interactions
have an important role in directing osteoblastic differentiation of calvarial osteoblasts.
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Introduction
Craniosynostosis (CS), the premature fusion of cranial sutures, is
a congenital defect occurring in one in 2000 live births.[1,2] Sutural
ossification occurs at the osteogenic front of cranial sutures through
direct (membranous) bone formation, and this process has been
largely attributed to increased osteogenic potential of resident
osteoblastic cells and mutations in a select number of genetic targets.
Osteoblasts and progenitor cells derived from both leporine and
human patients with craniosynostotic diseases exhibit increased
osteogenic potential in culture.[3,4,5] At the genetic level, mutations
in at least seven genes (FGFR1, FGFR2, FGFR3, TWIST1, EFNB1,
MSX2 and RAB23) result in enhanced ossification of the sutures in
CS patients.[6] Most of these genes harbor gain-of-function
mutations, while mutations in TWIST, an upstream repressor of
FGFR (fibroblast growth factor receptor) genes, induces loss of
function leading to constitutive overexpression of these genes. These
data suggest that abnormalities in growth factor signaling via FGFR
contribute to the rate of suture fusion.[7,8].
In addition to the activity of resident cells, calvarial bone
formation is directed by the presence and activity of various
growth factors secreted by the underlying dura mater.[9,10]
Specifically, the dural production of growth factors such as
transforming growth factor-beta 1 (TGF-b1) and basic fibroblast
growth factor (FGF-2), as well as the absence of inhibitors of bone
formation (e.g., noggin) correlate to the timing and location of
suture fusion in rodent and rabbit models.[11,12] The identifica-
tion of these molecules during development has led to the delivery
of antibodies and inhibitors as a proposed treatment option to slow
synostosis.[13] However, this approach suffers from short- and
long-term difficulties due to challenges in timing and stability of
delivering such large molecules to the defect site.
The extracellular matrix (ECM) plays a critical role in directing
the behavior of surrounding bone cells by instructing various
processes including cellular proliferation, differentiation, and
regulating the transport and signaling of endogenous osteoinduc-
tive growth factors.[14,15] While osteoblasts from craniosynostotic
patients appear to possess enhanced osteogenic potential, the
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contribution of the surrounding ECM to regulating growth factor
signaling to neighboring cells has been largely unexplored.
Differences in ECM composition, particularly glycosaminoglycans
and proteoglycans, may alter the osteogenic profile of responsive
osteoblasts due to availability of binding sites for endogenous
osteoinductive molecules.[16] Chondroitin sulfate proteoglycans
such as biglycan and decorin are involved in regulating postnatal
skeletal growth and osteogenic differentiation of mesenchymal
stem cells (MSCs) and preosteoblasts in culture.[17] The treatment
of cell-produced ECMs with heparanase and chondroitinase to
cleave heparan sulfate and chondroitin sulfate glycosaminoglycans
the proximal binding sites for osteoinductive proteins, resulted in
increased osteogenic differentiation of MSCs in culture due to
continued BMP signaling.[18,19] In light of previous reports
describing the role of proteoglycans on growth factor binding, the
purpose of this paper was to examine the role of ECM
composition derived from calvarial osteoblasts on osteoinductive
protein binding and its resultant effect on cell phenotype.
We hypothesized that calvarial osteoblasts from patients
diagnosed with CS secrete ECMs that differentially bind
osteoinductive proteins compared to cells from unaffected control
individuals (CI), and the resulting binding capacity would
subsequently modulate the osteogenic potential of associated cells.
To test this hypothesis, decellularized ECMs were produced by
calvarial osteoblasts from CS patients or unaffected CI, TGF-b1
or BMP-2 was adsorbed to each ECM, and the affinity of each
protein for the ECMs was quantified. These two osteoinductive
molecules were selected due to their presence and role in
contributing to sutural fusion.[12,13] To further explore the
interplay between growth factor-ECM interactions and osteogenic
response, osteoblast-secreted ECMs were enzymatically modified
to reduce heparan sulfate and chondroitin sulfate proteoglycans,
after which the affinity of each growth factor was characterized
and the resultant effect on osteogenesis was assessed.
Results
Differential binding of osteoinductive proteins to
osteoblast-produced ECMs
We examined the adsorption of TGF-b1 and BMP-2 when
exposed to ECMs secreted by calvarial osteoblasts derived from CI
and CS patients by observing protein distribution and quantifying
fluorescence. ECMs produced by CSObs contained significantly
more total protein (1.15 6 0.17 mg/ml) compared to ECMs
secreted by CIObs (0.756 6 0.02 mg/ml; p,0.01); hence, bound
growth factor concentrations were normalized to total protein
concentrations. Under fluorescence and brightfield microscopy,
we observed greater ECM deposition by CSObs compared to
ECMs secreted by CIObs, and proteins adsorbed to these ECMs
with broad spatial distribution (Fig. 1). The dissociation constant
(Kd) for each protein was then calculated by quantifying the
amount of free (unbound) protein and analyzed by a Scatchard
plot. TGF-b1 maintained a significantly higher Kd, and thus lower
binding affinity in ECMs secreted by CSObs than CIObs (p,0.05)
(Fig. 2A, 2B). No significant differences in BMP-2 binding were
observed between the two ECMs (Fig. 2C, 2D). Importantly,
Figure 1. Overlay images (bright field and fluorescent) of TGF-b1 (0.05 ng/ml) (A, B) and BMP-2 (0.04 ng/ml) (C, D) bound to ECMs
produced by CSObs (A, C) and CIObs (B, D). Images are representative of experiments performed in triplicate and are taken at 100x
magnification; scale bars represent 50 mm.
doi:10.1371/journal.pone.0025990.g001
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BMP-2 exhibited substantially greater affinity for the ECMs,
regardless of the cell source, compared to TGF-b1, as seen by the
lower Kd values. We observed similar results when adsorbing
growth factors to ECMs deposited at 21% O2 (data not shown),
demonstrating that oxygen tension did not have a significant effect
on the availability and composition of binding sites within these
osteoblast-secreted ECMs.
Characterization of ECM composition
We examined the presence of cell-secreted mineral within
decellularized osteoblast-secreted ECMs by Alizarin red staining
to determine if differences in mineral content might contribute to
differential protein binding. No evident staining was observed for
ECMs produced by either osteoblast population (data not shown).
Next, we aimed to determine the effect of culturing cells in the
presence of enzymes that interfere with GAG and proteoglycan
content and binding to core proteins. Decellularized ECMs were
stained with Alcian blue to qualitatively observe the effect of
enzyme treatment on GAG content. Optical microscopy images
confirmed increased Alcian blue staining in the untreated groups
compared to ECMs grown in the presence of heparanase and/or
chondroitinase ABC (Fig. 3A, 3B). The qualitative findings were
confirmed by quantification of dye intensity, with significantly
lower GAG content in treated versus control (untreated) groups
(Fig. 3C). Although we failed to appreciate significant differences
between ECMs treated with different enzymes, ECMs produced
by CSObs consistently contained more GAG content compared to
ECMs secreted by CIObs.
The presence of DCN, BGN, SYN-2, FN, and COL1 in
enzyme-treated and untreated ECMs was examined with
immunohistochemical staining (Fig. 4). Although the different
enzyme treatment groups resulted in similar staining intensities,
ECMs secreted by CSObs exhibited substantially darker staining
for DCN, BGN, SYN-2, COLI and FN compared to ECMs
produced by CIObs for all groups.
Enzyme-treated ECMs modulate osteogenic response of
CSObs
We used qPCR to measure the osteogenic response of CSObs
when seeded on ECMs produced by CSObs or CIObs deposited
in the presence of GAG-interfering enzymes (Fig. 5). We did not
detect stark differences in gene expression for cells grown on
ECMs in the presence of individual enzymes versus joint
administration. Therefore, we elected to present only qPCR for
cells seeded on ECMs deposited simultaneously with both
heparanase and chondroitinase (enzyme-treated group). After 5
days, CSObs demonstrated significantly less ALP expression on
all ECMs except the enzyme-treated CIObs ECM compared to
untreated CIObs ECM and TCP, while culture for 10 days
revealed consistent inhibition of ALP expression for all ECMs
(Fig. 5A). We observed a similar pattern for both RUNX2
(Fig. 5B) and DCN (Fig. 5D). COL1A expression in CSObs was
Figure 2. Scatchard plot analysis of TGF-b1 and BMP-2 binding to ECMs secreted by CSObs (A, C) and CIObs (B, D). Scatchard plot for
representative data set in each culture condition is included as inset. Plots are representative of experiments performed in triplicate. Kd represents the
dissociation constant.
doi:10.1371/journal.pone.0025990.g002
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reduced for cells grown on all ECMs compared to TCP control
after 5 days. However, after 10 days COL1A expression was
reduced only in CSObs grown on enzyme-treated CIObs ECM
compared to all other groups (Fig. 5C). We examined mRNA
expression of DCN and BGN in reseeded CSObs to probe if cells
would attempt to replenish an enzymatically-treated matrix. At 5
days, BGN mRNA levels were significantly higher in CSObs on
enzyme-treated CIObs ECM compared to cells grown on
untreated CIObs ECM, but mRNA levels were all significantly
lower than cells on TCP (Fig. 5E). This response was not
Figure 3. Alcian Blue stains of GAGs present in ECMs produced by CSObs (A) and CIObs (B) after heparanase (HS), chondroitinase
ABC (CABC), both enzymes (BOTH) and without (CONTROL) enzyme treatment. Images taken at 100X magnification; scale bars represent
50 mm. C: Quantification of Alcian blue stain. *p,0.05 vs. control, #p,0.05 vs. CIObs ECM.
doi:10.1371/journal.pone.0025990.g003
Figure 4. Immunohistochemical staining of molecules contained with ECMs secreted by CSObs (A) and CIObs (B). From left to right,
images for decorin (DCN), biglycan (BGN), collagen type 1 (COLI), syndecan-2 (SYN-2), and fibronectin (FN). Images are taken at 40x magnification;
scale bars represent 100 mm.
doi:10.1371/journal.pone.0025990.g004
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observed for CSObs seeded on cell-matched ECMs. However,
BGN expression increased after 10 days for cells on untreated
ECMs produced by CIObs versus enzyme-treated platforms. To
determine if changes in gene expression altered the downstream
osteogenic response, we quantified calcium deposition by CSObs
cultured on ECMs secreted by CIObs versus native ECMs
(Fig. 5F). After 5 and 10 days, CSObs cultured on ECMs
secreted by CIObs ECM exhibited significantly lower amounts of
deposited calcium compared to those cultured on native ECM,
regardless of the enzyme treatment. When examining the
behavior of CIObs on ECMs produced by CSObs, we observed
significantly greater ALP expression in CIObs after 5 days
compared to CIObs seeded on ECMs produced by CIObs
(Fig. 6A). Similar trends were observed for RUNX2 (Fig. 6B),
COLIA (Fig. 6C), and calcium deposition (Fig. 6D) after 10 days,
thus demonstrating the osteogenic potential of ECMs secreted by
CSObs.
Growth factor binding is altered by enzyme treatment of
ECMs
The deposition of osteoblast-secreted ECMs in the presence of
heparanase, CABC, or both enzymes resulted in significantly
increased values of Kd for both TGF-b1 and BMP-2 as compared
to untreated ECMs, confirming reduced protein binding for these
matrices (Table 1). Furthermore, the application of both enzymes
significantly reduced protein binding compared to ECMs
produced by a singular enzyme. Similar to data collected without
enzyme treatment (Fig. 2A-B), Kd was significantly higher and
thus binding of TGF-b1 was lower for enzyme-treated ECMs
deposited by CSObs compared to CIObs-secreted ECMs. We did
not observe significant differences in BMP-2 binding between
enzyme-treated ECMs deposited by either osteoblast population,
perhaps due to the enzyme concentration used. However, BMP-2
binding was reduced on enzyme-treated ECMs compared to
untreated ECMs, thus confirming the efficacy of removing protein
binding sites during enzyme treatment.
Differential binding of growth factors to enzyme-treated
ECMs modulates osteogenic response
After determining differences in the osteogenic response of cells
seeded on ECMs and protein binding on enzyme-treated
substrates, we examined the osteogenic response of CSObs when
seeded on ECMs and cultured in the presence of TGF-b1 or
BMP-2. In the absence of osteoinductive proteins, the osteogenic
response of CSObs seeded on ECMs produced by CIObs was
lower than those seeded on ECMs produced by CSObs. Thus, we
characterized osteogenic potential of CSObs seeded on CIObs-
produced ECM in the presence of either osteoinductive protein to
detect greater differences due to each stimulus (Fig. 7). In the
presence of exogenous TGF-b1, cells cultured on enzyme-treated
Figure 5. Quantitative PCR results for genes monitored in CSObs when seeded on enzyme- treated or untreated ECM from CSObs
or CIObs or TCP: ALP (A), RUNX2 (B), COL1A (C), DCN (D), BGN (E), and calcium deposition (F). Values reflect fold change in the target mRNA
expression over RPL13. #p,0.05 vs. untreated ECM; *p,0.05 vs. TCP.
doi:10.1371/journal.pone.0025990.g005
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ECM exhibited lower ALP expression after 5 and 10 days
compared to cells on untreated ECM. Conversely, RUNX2
expression was greater for cells on enzyme-treated ECMs with
TGF-b1. Despite differential binding of TGF-b1 to enzyme-
treated versus untreated ECMs, we did not detect differences in
COL1A expression at 5 or 10 days, yet mRNA expression in both
groups was significantly lower than cells cultured on TCP in the
presence of TGF-b1. After 10 days, the amount of calcium
deposited by cells seeded on enzyme-treated ECMs stimulated
with TGF-b1 was significantly lower compared to cells on
untreated ECMs. In the presence of BMP-2, the expression of
each osteogenic gene was significantly lower in CSObs cultured on
enzyme-treated ECMs compared to cells on untreated ECMs at 5
and 10 days. We detected a similar trend in calcium deposition at
5 and 10 days.
Discussion
The ossification of developing human calvarial tissue is a
complex process dependent upon the coordination of endogenous
osteoinductive signaling cues and the osteogenic potential of
responsive cells. Craniosynostosis, the premature fusion of the
cranial sutures, restricts brain growth and requires surgical
intervention to provide space for normal development. To
investigate causality of this disease state, a significant portion of
studies have focused on genetic mutations involving FGF receptors
and DNA binding proteins such as MSX2 and TWIST [20]. In
addition, others have shown differences in local TGF-b1 and
insulin-like growth factor (IGF1) between patent and fused sutures
Figure 6. Quantitative PCR results for genes monitored in CIObs when seeded on enzyme- treated or untreated ECM from CSObs or
CIObs or TCP: ALP (A), RUNX2 (B), COL1A (C), and calcium deposition (D). Values reflect fold change in the target mRNA expression over
RPL13. #p,0.05 vs. untreated ECM; *p,0.05 vs. TCP; $p,0.05 vs. CSObs ECM.
doi:10.1371/journal.pone.0025990.g006
Table 1. Dissociation constants (Kd) for TGF-b1 and BMP-2
binding to enzyme-treated ECMs.
Enzyme
treatment TGF-b1 Kd (ng/ml) BMP-2 Kd (ng/ml)
CIObs CSObs CIObs CSObs
heparanase 0.56660.05# 1.49360.002#* 0.25660.004# 0.266360.021#
chondroitinase 0.64460.04# 1.30160.009#* 0.26860.039# 0.28860.018#
Both enzymes 1.49660.03 2.33760.279* 0.45460.043 0.46060.044
None 0.45960.07# 0.73460.017#* 0.028960.002# 0.02460.002#
Values are represented as mean 6 std. dev. (n = 3).
*p,0.05 vs. corresponding CIObs ECM, #p,0.05 vs. both enzymes.
doi:10.1371/journal.pone.0025990.t001
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[21], hence leading to recent therapeutic approaches of blocking
the activity of these constituents with local antibody delivery.
However, current treatment methods for craniosynostosis lack
techniques to slow the increased osteogenic potential of native
osteoblasts, and the contribution of the surrounding ECM is
unclear. The results of this study demonstrate that cell-secreted
ECMs exhibit differential interaction with osteoinductive cues,
potentially providing a new target for treating patients diagnosed
with craniosynostosis.
The interaction between cells and the surrounding ECM is critical
to instruct cell phenotype, and these interactions have been examined
in vitro and in vivo [22,23]. The characterization of this behavior in vitro
is commonly simplified to examining cell behavior on individual
ECM proteins or on tissue culture plastic, yet the situation in vivo is
more complicated, involving the interaction of cells with a complex
array of proteins and polysaccharides. Thus, the use of cell-secreted
decellularized ECMs provides a more physiologically relevant tool to
explore the role of the ECM on cell behavior. We and others have
demonstrated how decellularized ECMs can be used to control the
cell fate process at different stages of differentiation.[14,24] The
results of our study confirm reduced binding of TGF-b1 to ECMs
deposited by CSObs compared to CIObs. These results agree with
previous studies where decreased TGF-b1 expression was detected in
fused sagittal sutures compared to patent posterior frontal su-
tures.[25] Although the exact mechanism of TGF-b1 activity in bone
formation is not clearly understood, TGF-b1 plays a major role in the
bone remodeling process by regulating bone resorption.[26] Hence,
reduced binding affinity of TGF-b1 to ECMs secreted by CSObs
may contribute to increased bone formation seen in patients
diagnosed with craniosynostosis.
Constituents of the ECM, particularly proteoglycans, play an
important role in regulating the binding, transport, and signaling
of various growth factors including TGF-b1 and BMP-2.[27]
Upon analyzing the ECM secreted by various osteoblastic
populations, others have reported differences in the expression of
proteins including syndecan, decorin, and biglycan in normal
osteoblasts versus those isolated from patients diagnosed with
syndromic craniosynostosis.[16] The presence of biglycan and
decorin has been closely associated with BMP-2 and TGF-b1
signaling, respectively.[28,29] The increased amounts of decorin
and biglycan in ECMs secreted by CSObs compared to CIObs
likely represent a significant contribution to differences in growth
factor binding to each ECM. This is in agreement with earlier
studies demonstrating that the sulfated chondroitin sulfate
structures on the surface of osteoblasts enhance osteogenic activity
due to increased BMP-2 binding.[30] In addition to its effect on
osteoblast activity, certain chondroitin sulfate units reduced
osteoclast activity and impaired bone resorption.[31]
These data support previous results that demonstrate the
osteogenic differentiation of cells of the osteoblastic lineage can
Figure 7. Quantitative PCR results for genes monitored in CSObs seeded on enzyme-treated or untreated ECM from CIObs or TCP
control in the presence of TGF-b1 or BMP-2: ALP (A), RUNX2 (B), COL1A (C), and calcium deposition (D). Values reflect fold change in the
target mRNA expression over RPL13. #p,0.05 vs. untreated ECM, *p,0.05 vs. TCP.
doi:10.1371/journal.pone.0025990.g007
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be modulated in the presence of GAG-modifying enzymes.[17,32]
When cultured on enzyme-treated ECMs produced by CIObs for
short periods, we observed that osteoblasts from craniosynostosis
patients exhibited increased expression of ALP and RUNX2, both
early indicators of osteogenesis, compared to cells cultured on
untreated ECMs. This is consistent with reports of rare RUNX2
duplications in CS patients.[33] Also, this increase in ALP at
earlier time points could be attributed to the lower amount of ALP
present in enzyme treated CIObs ECMs compared to the ECMs
secreted by CSOBs. However, CSObs exhibited significant
reductions in COL1A expression at 10 days when cultured on
enzyme-treated substrates compared to untreated ECMs or TCP.
Furthermore, increased decorin and biglycan within ECMs
deposited by CSObs, even after enzyme treatment, may promote
binding of endogenous BMP-2 compared to ECMs produced by
normal osteoblasts, thus resulting in early increases in osteoblast
activity. Despite significant increases in ALP and RUNX2
expression, we did not detect differences in calcium deposition
by CSObs on ECMs deposited by CIObs. These data suggest that
CSObs are responsive to changes in their environment, suggesting
that CSObs rapidly remodel the underlying matrix or lack
necessary sensitivity to exhibit differences in mineral content. The
temporal response of CSObs to an underlying ECM merits further
investigation to fully understand how these cells remodel their
surroundings and undergo osteogenic differentiation. We also
observed that CSObs cultured on enzyme-treated ECMs pro-
duced by CIObs responded with increased early DCN and BGN
expression compared to cells on untreated ECMs. The lack of
significance in BGN expression from cells on CSObs ECM could
be attributed to greater concentrations of biglycan within these
ECMs. These results confirm differences in the amount of DCN
and BGN present in the enzyme-treated ECM in comparison to
the untreated ECMs from both cell types.
To verify if the enzyme-modulated ECMs would exhibit
impaired protein binding and resultant decreases in osteogenic
markers in CSObs, we calculated the binding affinity of TGF-b1
and BMP-2 on the enzyme-treated ECMs. As expected, enzyme-
treated ECMs had significantly higher Kd values (reduced binding)
for both proteins compared to the untreated groups. TGF-b1
stimulates proliferation of osteoprogenitor cells and inhibits
differentiation of mature osteoblasts.[34] BMP-2 is a potent
inducer of osteoblastic differentiation. By stripping the ECMs of
binding sites for these proteins, it may be possible to impair
osteoblastic activity of CSObs. These data support this hypothesis,
as we did not detect significant increases in expression of mRNA
for ALP, RUNX2, or COL1A for cells cultured on enzyme-treated
ECMs in the presence of TGF-b1. Moreover, CSObs cultured on
enzyme-treated ECMs in the presence of exogenous BMP-2
consistently exhibited reduced expression of these three markers
compared to cells on untreated ECMs.
These data demonstrate that binding of osteoinductive proteins
to underlying cell-secreted ECMs and resultant osteogenic
signaling is distinct between patients diagnosed with premature
cranial fusion and healthy controls. These differences are
attributed to the composition and activity of ECM constituents
such as proteoglycans and not simply due to the presence of highly
hydrophilic hydroxyapatite deposited by active osteoblasts.
Collectively, these data suggest that the increased osteogenic
potential of osteoblasts from craniosynostosis patients is at least
partially derived from differences in the local presentation of
endogenous osteoinductive proteins from the surrounding ECM.
The ECM may serve as a means for the local osteogenic cells to
modulate the effects of the various growth factors. While a more
thorough characterization of the ECM protein-cytokine interac-
tion is necessary to completely understand the signaling mecha-
nism in these cells, the use of enzyme treatment provides an
additional tool to reduce the binding of endogenous BMP-2
binding which may be useful in reducing osteoblast activity of
native cells.
Materials and Methods
Ethics statement
All specimens were obtained following informed written consent
according to an approved protocol granted by the Institution
Review Board at the University of California, Davis. All patients
with coronal craniosynostosis were clinically assessed and found to
have nonsyndromic coronal craniosynostosis without associated
extracranial congenital anomalies or developmental delays.
Cell culture and ECM production
Osteoblasts were isolated from bone fragments following
suturectomy as treatment for nonsyndromic craniosynostosis
(CSObs), while normal calvarial osteoblasts (CIObs) were isolated
from cranial bones of children undergoing surgical intervention for
head trauma. Genetic analysis excluded mutations associated with
syndromic forms of craniosynostosis in the relevant exons of
FGFR1, FGFR2, FGFR3 and TWIST genes as described by
Boyadjiev et al. [2] Osteoblasts were maintained in Dulbecco’s
modified eagle’s medium (DMEM, Invitrogen) containing 10%
fetal bovine serum (FBS, JR Scientific) and 1% penicillin-
streptomycin (Mediatech). Cells were used at passages 4-6. At
confluence, cells were trypsinized and seeded in 24 well plates at
30,000 cells/cm2 and cultured in maintenance media (DMEM/
10% FBS). After 24 h, the media was replaced with osteogenic
media (maintenance media containing 10 nM dexamethasone,
50 mg/ml ascorbate-2-phosphate, and 10 mM b-glycerophos-
phate, all from Sigma), and the cells were cultured for another 5 d.
The cells were cultured in 5% or 21% oxygen as previously
described.[35] After 5 d, osteoblast-secreted ECMs were decel-
lularized by incubation in phosphate buffered saline (PBS)
containing 20 mM NH4OH and 0.5% (w/v) Triton-X for 15
min at 37uC.[14] ECMs were treated with PBS containing DNase
(100 units/ml; Sigma) for 1 h, and resulting ECMs were then
rinsed with PBS, air dried, and used immediately for subsequent
experiments. Total protein concentrations in the ECMs were
measured using Amido black staining.[36]
Adsorption of growth factors to osteoblast-secreted
ECMs
Recombinant human TGF-b1 and BMP-2 (Peprotech) were
reconstituted to a final concentration of 1 mg/ml in PBS
containing bovine serum albumin (BSA) as a carrier. The growth
factors were fluorescently labeled using the Dylight 488 labeling kit
(Pierce Biotechnology) as described by the manufacturer. Briefly,
the growth factors were incubated with the fluorescent dye for 1 h
at room temperature. The unincorporated dye was removed by
passing the mix through a desalting spin column. The labeled
growth factors were diluted in PBS to obtain a range of
concentrations from 0 to 200 ng/ml. ECMs prepared as described
above were incubated overnight at 4uC with 200 ml of PBS
containing either TGF-b1 or BMP-2 at different concentrations.
After 24 h, the growth factor solution was collected, ECMs were
rinsed twice with PBS to remove unbound growth factor, and the
distribution of bound protein on ECMs was imaged using a Nikon
Eclipse TE2000-U fluorescent microscope. Growth factor-bound
ECMs were then scraped in PBS (100 ml/well) using a cell scraper,
and bound concentrations of each protein were quantified via
Growth Factor Adsorption to Extracellular Matrices
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fluorescence (excitation: 493 nm, emission: 518 nm) with a plate
reader (Synergy HTTR, Biotek). Growth factor concentration was
calculated from a standard curve corrected for BSA. All
concentrations were normalized to ECM protein concentrations,
and the dissociation constants (Kd) were calculated from a
Scatchard plot analysis using Prism (GraphPad Software, Inc.).
[37]
Enzymatic treatment of ECMs
Osteoblasts were seeded in 24 well plates at 30,000 cells/cm2 in
maintenance media. After 24 h, the media was changed to serum-
free osteogenic media containing heparanase (heparanase I, II, III;
1.2 mU/ml) and/or chondroitinase ABC (50 mU/ml, both from
Sigma) to disrupt GAG formation. The cells were cultured for an
additional 5 d with the medium changed every 3 d. ECMs
deposited by cells without enzyme treatment served as controls.
The ECMs were then decellularized as described above. Binding
constants for TGF-b1 and BMP-2 on enzyme-treated ECMs were
quantified by Scatchard plot analysis.
ECMs were reseeded with CSObs or CIObs at 30,000 cells/cm2
and cultured in 5% O2 and osteogenic media for up to 10 d. The
expression of osteogenic markers including alkaline phosphatase
(ALP), runt-related transcription factor 2 (RUNX2), and collagen-Ia
(COL1A) was evaluated using qPCR.[38] Briefly, ECMs were rinsed
with PBS and total RNA was collected using the RNeasy Mini kit
(Qiagen). 300 ng of total RNA was reverse-transcribed with
Superscript II Reverse Transcriptase (Invitrogen). qPCR was
performed using the TaqMan1 Universal PCR Master Mix (Applied
Biosystems) on a Mastercycler1 Realplex2 (Eppendorf). Primers for
ALP, COL1A, RUNX2, decorin (DCN), biglycan (BGN), and RPL13
were purchased from Applied Biosystems. Amplification conditions
were 50uC for 2 min, 95uC for 10 min, followed by 40 cycles at 95uC
for 15 s and 60uC for 1min. Quantitative gene expression values were
normalized to RPL13 and presented as DCt values calculated as fold
change in gene expression with respect to expression of the
housekeeping gene. Mineralization was quantified by measuring
calcium deposition as in indicator of late stage osteoblastic
differentiation. Osteoblasts seeded on ECMs were collected in 0.9N
sulfuric acid and incubated at 37uC overnight. Non-cell seeded
ECMs were considered as background to account for any calcium
present in the ECMs. Calcium content was quantitatively assessed
using the OCPC calorimetric method.[39] Calcium deposited by
cells after culturing on the different ECMs was calculated by
subtracting the background from total calcium levels.
We further studied the expression of osteogenic markers by
osteoblasts seeded on enzymatically-treated ECMs when supple-
mented with exogenous TGF-b1 or BMP-2. After decellulariza-
tion, enzyme-treated ECMs produced by CIObs were seeded with
CSObs at 30,000 cells/cm2 and cultured in serum-free osteogenic
media containing either 10 ng/ml TGF-ß1 or 100 ng/ml BMP-2.
CSObs seeded on non-enzyme treated CIObs-produced ECMs or
directly on tissue culture plastic (TCP) and maintained in growth
factor-supplemented media served as controls.
Characterization of ECMs
Staining for GAG and mineral content. Enzyme treated
ECMs were prepared as described above in the presence or
absence of disrupting enzymes. GAG content within ECMs was
quantified using an Alcian blue stain.[40] Briefly, ECMs were
rinsed in distilled H2O, and then incubated overnight in 0.1 N
HCl containing 0.1% Alcian blue (Sigma). The ECMs were rinsed
three times in distilled H2O, extracted using 200 ml of 0.1N HCl,
and absorbance was measured at 620 nm. The presence of mineral
in enzyme-treated and native ECMs was qualitatively assessed
using Alizarin red staining.[41]
Immunohistochemical staining of ECMs to observe
composition. The presence of collagen 1, BGN, syndecan-2
(SYN-2), and fibronectin (FN) in ECMs was examined using
immunohistochemical staining with human primary antibodies
(Santa Cruz Biotechnology) performed with a mouse specific HRP/
DAB detection kit (Abcam) following the manufacturer’s
instructions. Briefly, ECMs were blocked with 200 ml/well of
H2O2 for 10 min, followed by three rinses with wash buffer (10%
TBST, 1% Tween). ECMs were further blocked in 200 ml/well of
protein block to prevent nonspecific protein binding. ECMs were
then incubated overnight at 4uC with specific primary antibodies
(1:50 dilution in PBS containing 2% (v/v) protein block). Controls
were incubated in buffer solution. After rinsing, biotinylated goat
anti-mouse IgGwas applied for 30min at room temperature, ECMs
were rinsed, and streptavidin peroxidase was applied for 10 min.
After rinsing, 200 ml of the DAB chromogen-substrate complex
(20 ml chromogen to 1 ml substrate) was applied to each well for 10
min. The ECMs were rinsed in tap water 7-8 times, air dried, and
imaged using a Nikon Eclipse TE2000-U microscope.
Statistical analysis
Results are expressed as mean 6 standard deviation of the
mean. All assays were performed in triplicate unless otherwise
mentioned. Statistical significance was determined using the
Bonferroni post-hoc test and probability values (p) , 0.05 were
considered significant.
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